CytoMed Therapeutics (NASDAQ:GDTC) Stock Price Up 1% – Here’s Why

CytoMed Therapeutics Limited (NASDAQ:GDTC)’s stock price shot up 1% during mid-day trading on Thursday . The stock traded as high as $1.03 and last traded at $1.03. 26,434 shares were traded during trading, a decline of 98% from the average session volume of 1,726,968 shares. The stock had previously closed at $1.02.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of CytoMed Therapeutics in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, CytoMed Therapeutics currently has an average rating of “Sell”.

CytoMed Therapeutics Stock Up 1.9%

The firm’s fifty day moving average is $1.17 and its 200-day moving average is $1.70.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.